A Clinical Study to Investigate Safety, Tolerability, and Preliminary Efficacy of mRNA Encoding CD19/CD3 T Cell Engager (ABO2203) in Adult Patients With Relapsed or Refractory B-NHL
Status: Recruiting
Location: See location...
Intervention Type: Drug
Study Type: Interventional
Study Phase: Phase 1
SUMMARY
The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, as well as preliminary efficacy of mRNA encoding CD19/CD3 T cell engager (ABO2203) in adult patients with relapsed or refractory CD19-positive B-NHL, This study included dose escalation and dose expansion parts.
Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Maximum Age: 75
Healthy Volunteers: f
View:
• ≥18 years and ≤75 years of age at time of informed consent
• Participants with histologically and/or cytologically confirmed relapsed or refractory CD19-positive B-cell non-Hodgkin lymphoma
• With at least one of evaluable/measurable target lesions per Lugano 2014 criteria
• Eastern Cooperative Oncology Group (ECOG) performance status score of 0-2
• Life expectancy of ≥3 months
• Sufficient organ function
Locations
Other Locations
China
Ruijin Hospital
RECRUITING
Shanghai
Contact Information
Primary
Pei miao Zhang
pm.zhang@wiseon.cn
010-57593072
Time Frame
Start Date: 2025-05-26
Estimated Completion Date: 2027-05
Participants
Target number of participants: 56
Treatments
Experimental: A study of mRNA encoding CD19/CD3 T cell engager (ABO2203) in patients with relapsed or refractory B
ABO2203
Related Therapeutic Areas
Sponsors
Leads: Ruijin Hospital